TY  - JOUR

T1  - Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

JO  - BMJ Open

UR  - http://dx.doi.org/10.1136/bmjopen-2023-083582

PY  - 2024/02/05

AU  - Brittain G

AU  - Petrie J

AU  - Duffy KEM

AU  - Glover R

AU  - Hullock K

AU  - Papaioannou D

AU  - Roldan E

AU  - Beecher C

AU  - Bursnall M

AU  - Ciccarelli O

AU  - Coles AJ et al

ED  - 

DO  - DOI: 10.1136/bmjopen-2023-083582

PB  - BMJ

VL  - 14

IS  - 2

SP  - e083582

EP  - e083582

Y2  - 2024/09/20

ER  -